Catalyst Wire Dossier Catalyst Wire Dossier

Sugammadex (MK-8616)

Sugammadex · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sugammadex (MK-8616), covering 2024-09-26 to 2024-09-26. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) [Phase 4]

See pricing